LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes

The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in high-risk adults with type 2 diabetes, expanding the drug's label beyond glucose control. In a 13,299-patient trial, Mounjaro demonstrated an 8% lower MACE-3 rate compared to LLY's own Trulicity, meeting non-inferiority endpoints.

The approval comes as Mounjaro posted $18.6 billion in first-half 2026 sales. The cardiovascular indication positions the drug to compete more directly with NVO's Ozempic, which already carries a cardiovascular benefit claim. The expanded label could accelerate market share gains in the crowded GLP-1 space, where payers and prescribers increasingly weigh cardiac outcomes data alongside metabolic efficacy.

LLY has leveraged Mounjaro's dual GIP/GLP-1 mechanism to differentiate from single-receptor agonists. The cardiovascular nod strengthens that positioning and may support premium pricing in formulary negotiations.